SCHEMBL5660280

SCHEMBL5660280

O=C1C(=O)N(Cc2ccccc2Cl)c2cccc(Cl)c21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.51
CHRM5 P08912 1/20 0.50
TSHR P16473 3/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
P2RX7 Q99572 2/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.44
CES1 P23141 3/20 0.44
BCHE P06276 2/20 0.44
CES2 O00748 1/20 0.44
ALDH1A1 P00352 3/20 0.44
ALDH2 P05091 1/20 0.44
CHRM1 P11229 1/20 0.44
ALDH3A1 P30838 1/20 0.44
APAF1 O14727 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30967408 0.86 ALDH1A1 (0.61) CHRM5TSHRCYP1A2CES1BCHE
SCHEMBL4609842 0.83 CES1 (0.66) LMNACHRM5TSHRCYP1A2MEN1
SCHEMBL18954692 0.76 CES1 (0.60) CHRM5TSHRCYP1A2P2RX7CES1
SCHEMBL30937982 0.76 CHRM5 (0.65) CHRM5TSHRCYP1A2CES1BCHE
SCHEMBL3010654 0.75 CA12 (0.49) CYP1A2MEN1KMT2APOLBALDH1A1
SCHEMBL9904848 0.75 ALDH3A1 (0.72) CHRM5CES1BCHECES2ALDH1A1
SCHEMBL4802311 0.74 PTGS1 (0.61) LMNATSHRCYP1A2CYP2C9CYP2C19
SCHEMBL7559102 0.74 SMN1; SMN2 (0.55) LMNATSHRCYP1A2CYP2C9CYP2C19
SCHEMBL12857524 0.74 CASP3 (0.65) LMNACHRM5CYP1A2CYP2C19HTT
SCHEMBL30498849 0.74 ALDH1A1 (0.58) CHRM5TSHRCYP1A2HTTCES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 US disclosed
EP-1487792-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-12-22 EP disclosed
WO-2003078394-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 LMNA 3323/4885CHRM5 1591/4885TSHR 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.